Validation of Valosin-Containing Protein (VCP) as a Therapeutic Target for Triple Negative Breast Cancer

Authors

Margaret Y. Han, Rice UniversityFollow
Yanxia Ma, The University of Texas MD Anderson Cancer Center
William M. Tahaney, The University of Texas MD Anderson Cancer Center
Jing Qian, The University of Texas MD Anderson Cancer Center
Abhijit Mazumdar, The University of Texas MD Anderson Cancer Center
Powel H. Brown, The University of Texas MD Anderson Cancer Center

Files

Publisher

The University of Texas MD Anderson Cancer Center

City

Houston

Keywords

valosin containing protein (VCP), SOX9, triple-negative breast cancer, cell growth, survival

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Program Affiliation

CPRIT-CURE Summer Undergraduate Program

Recommended Citation

Han, Margaret Y.; Ma, Yanxia; Tahaney, William M.; Qian, Jing; Mazumdar, Abhijit; and Brown, Powel H., "Validation of Valosin-Containing Protein (VCP) as a Therapeutic Target for Triple Negative Breast Cancer" (2021). Summer Experience 2021. 187.
https://openworks.mdanderson.org/sumexp21/187